SHIM
NVCR icon

Stone House Investment Management’s NovoCure NVCR Stock Holding History

Stone House Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87 Buy
+8
New +$100 ﹤0.01% 1018
2025
Q4 		– Sell
-193
Closed -$2.49K – 906
2025
Q3 		$2.49K Buy
+193
New +$2.58K ﹤0.01% 457

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Stone House Investment Management's NVCR Position: Q1 2026 in Review

Stone House Investment Management opened a new position in NovoCure (NVCR) in Q1 2026: 8 shares worth $87. The stake represents ﹤0.01% of the portfolio and ranks #1018 among its holdings. This is a return to the name: Stone House Investment Management previously reported a position in NVCR as recently as Q3 2025.

Stone House Investment Management first reported a position in NVCR in Q3 2025 and has held it in 2 quarters since. The position peaked at $2.49K in Q3 2025. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Stone House Investment Management held 8 shares of NovoCure worth $87 as of Q1 2026.
  • NovoCure was a new Stone House Investment Management position in Q1 2026.
  • NovoCure made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #1018 holding.
  • Stone House Investment Management first reported a position in NovoCure in Q3 2025 and has held it in 2 quarters since.
  • Stone House Investment Management's NovoCure position peaked at $2.49K in Q3 2025.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.